Oral iron chelator desferrithiocin blocks allogeneic mononuclear cell activation and cytokine production in vivo and prolongs rat cardiac allograft survival.
Hancock
W W
WW
Department of Pathology and Immunology, Monash Medical School, Alfred Hospital, Melbourne, Australia.
Whitley
D
D
Kupiec-Weglinski
J W
JW
Tilney
N L
NL
D000818:Animals; D016207:Cytokines / Q000032:analysis / Q000096:biosynthesis*; D004095:Dihydropyridines / Q000627:therapeutic use*; D006085:Graft Survival; D016027:Heart Transplantation / Q000276:immunology* / Q000473:pathology; D007502:Iron Chelating Agents / Q000627:therapeutic use*; D008213:Lymphocyte Activation / Q000187:drug effects; D008262:Macrophage Activation / Q000187:drug effects; D051381:Rats; D011917:Rats, Inbred Lew; D011919:Rats, Inbred Strains; D015375:Receptors, Interleukin-2 / Q000032:analysis / Q000096:biosynthesis; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D013844:Thiazoles / Q000627:therapeutic use*; D014184:Transplantation, Homologous
D016207:Cytokines; D004095:Dihydropyridines; D007502:Iron Chelating Agents; D015375:Receptors, Interleukin-2; D013844:Thiazoles; C050223:desferrithiocin